Cross‑Modality Biomarker Trends: Federated, Compliant Oncology Trials
Analytical look at how federated architectures and cross‑modality biomarker workflows enable GDPR/HIPAA-compliant, adaptive oncology trials — and why patients can feel hopeful about more precise, accessible studies.
Robert Maxwell
Oct 20, 2025
Head and neck SCC
hormone-positive breast cancer
Atopic dermatitis trials
Gynecologic oncology analytics
